

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2637)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the annual general meeting (the “AGM”) of Fujian Haixi Pharmaceuticals Co., Ltd. (the “**Company**”) will be held at Conference Room, Floor 1, Block B, No. 177 Jinda Road, Jianxin Town, Cangshan District, Fuzhou, Fujian Province, the PRC on Wednesday, 27 May 2026 at 10:00 a.m. for the purpose of considering and, if thought fit, approving the following resolutions. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the circular of the Company dated 30 April 2026 (the “**Circular**”).

ORDINARY RESOLUTIONS

1. To consider and approve the Work Report of Board of Directors for 2025.
2. To consider and approve the Work Report of Board of Supervisors for 2025.
3. To consider and approve the Audited Consolidated Financial Statements for 2025 and independent auditor’s report for 2025.
4. To consider and approve 2025 Annual Report and ESG report.
5. To consider and approve the final accounts plan for 2025.
6. To consider and approve profit distribution plan for 2025.
7. To consider and approve the re-appointment of external auditor for 2026, and to authorize the Board to fix their remuneration.
8. To consider and approve the Directors’ remuneration for 2026.
9. To consider and approve the application to the banks for the comprehensive credit facilities for 2026 and provision of guarantees.

10. To consider and approve the abolishment of the Board of Supervisors.
11. To consider and approve the amendments to Rules of Procedure for Shareholders' Meeting.
12. To consider and approve the amendments to Rules of Procedure for Meeting of the Board of Directors.
13. The election of Directors of the second session of the Board of Directors:
 - a Proposal on the election of Mr. Kang Xinshan as an executive Director of the second session of the Board of Directors
 - b Proposal on the election of Ms. Feng Yan as an executive Director of the second session of the Board of Directors
 - c Proposal on the election of Dr. Chen Guangming as an executive Director of the second session of the Board of Directors
 - d Proposal on the election of Mr. Li Junqing (李俊青先生) as an executive Director of the second session of the Board of Directors
 - e Proposal on the election of Mr. Xu Dong as a non-executive Director of the second session of the Board of Directors
 - f Proposal on the election of Mr. Wang Xinkun as a non-executive Director of the second session of the Board of Directors
 - g Proposal on the election of Ms. Wang Shan Shan as an independent non-executive Director of the second session of the Board of Directors
 - h Proposal on the election of Ms. Pu Meiting as an independent non-executive Director of the second session of the Board of Directors
 - i Proposal on the election of Mr. Lin Bin (林斌先生) as an independent non-executive Director of the second session of the Board of Directors
14. To consider and approve the capital increase in Hong Kong subsidiary.

SPECIAL RESOLUTIONS

15. To consider and approve the amendments to the Articles of Association.
16. To consider and approve the formulation of the implementation plan for the share incentive scheme.

17. To consider and approve the general mandate to issue Shares.

18. To consider and approve the general mandate to repurchase Shares.

By order of the Board
Fujian Haixi Pharmaceuticals Co., Ltd.
Kang Xinshan
Executive Director, Chairman and General Manager

Hong Kong, 30 April 2026

As of the date of this notice, the Board comprises (i) Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi as executive Directors; (ii) Mr. Wang Xinkun and Mr. Xu Dong as non-executive Directors; and (iii) Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting as independent non-executive Directors.

Notes:

1. For further details of the resolutions, please refer to the circular of the Company dated 30 April 2026.
2. All resolutions at the AGM will be taken by poll pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”). The poll results will be published on the website of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) at www.hkexnews.hk and the Company’s website at www.hxpharma.com in accordance with the Listing Rules.
3. All Shareholders are eligible for attending the AGM. Any Shareholder of the Company entitled to attend and vote at the AGM convened by the above notice is entitled to appoint a proxy or more than one proxy to attend the AGM and vote instead of him/her. A proxy need not be a Shareholder. If more than one proxy is appointed, the number of Shares in respect of which each such proxy so appointed must be specified in the relevant proxy form. Every Shareholder present in person or by proxy shall be entitled to one vote for each Share held by him/her.
4. In order to be valid, the proxy form together with the power of attorney or other authority (if any) under which it is signed, or a notarially certified copy thereof, must be completed and returned to the Company’s H Share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong (for H Shareholders) not less than 24 hours before the time appointed for the AGM. Completion and return of the proxy form will not preclude a Shareholder from attending and voting at the AGM or any adjourned meeting thereof should he/she so wish.
5. For the purpose of determining the Shareholders’ eligibility to attend and vote at the AGM (and any adjourned meeting thereof), the register of members of the Company will be closed from Thursday, 21 May 2026 to Wednesday, 27 May 2026, both days inclusive, during which period no transfer of Shares will be registered. The record date will be Wednesday, 27 May 2026. In order for the H Shareholders to qualify for attending and voting at the AGM, all properly completed share transfer forms together with the relevant H share certificates shall be lodged with the Company’s H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Wednesday, 20 May 2026.
6. The AGM is expected to take no more than half a day. Shareholders who attend the AGM (in person or by proxy) shall bear their own travelling and accommodation expenses.

7. Shareholders who are entitled to attend and vote at the AGM may appoint one or more proxies to attend and vote on their behalf. A proxy need not be a Shareholder.
8. Shareholders or their proxies shall provide their identification documents when attending the AGM. In case of a corporate Shareholder, its proxy or other person authorized to attend the meeting with a resolution passed by the board of directors or other decision-making authorities of such corporate Shareholder, should provide a copy of such resolution.
9. In case of joint holders, the vote of the senior joint Shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint Shareholder(s) and for this purpose seniority will be determined by the order in which the names stand on the register of members of the Company in respect of the joint shareholding.
10. The contact of the Company:

Address: Fujian Haixi Pharmaceuticals Co., Ltd.
Floor 3&4, Block B, No. 177 Jinda Road
Jianxin Town, Cangshan District
Fuzhou, Fujian Province
the PRC

Postal Code: 350028

Contact Person: Zhang Junhuan (張俊環)

Email: junhuan.zhang@hxpharma.com